The state of dermatology drug development has been accelerating at an unprecedented rate for the last half-decade, with a myriad of targeted and novel therapy breakthroughs achieved in both common chronic diseases—like atopic dermatitis and psoriasis—and previously under-treated and psychosocially-affecting skin disorders—like alopecia areata and vitiligo. Drug options are becoming more robust, more versatile, and […]